Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001172661-25-003569
Filing Date
2025-08-14
Accepted
2025-08-14 20:53:34
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 8692
  Complete submission text file 0001172661-25-003569.txt   10450
Mailing Address 3730 KIRBY DRIVE SUITE 1200 HOUSTON TX 77098
Business Address 3730 KIRBY DRIVE SUITE 1200 HOUSTON TX 77098 (832) 384-1100
BELLICUM PHARMACEUTICALS, INC (Subject) CIK: 0001358403 (see all company filings)

EIN.: 201450200 | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-88493 | Film No.: 251222086
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 510 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10022
Business Address 510 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10022 (212) 231-4932
ARMISTICE CAPITAL, LLC (Filed by) CIK: 0001601086 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G